– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to...
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase...
PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader...
HUNTSVILLE, Ala., Jan. 9, 2025 /PRNewswire/ -- healthŌme®, Inc., a pioneering genomics-based precision health management company, today announced its renaming...
More than 50 peer-reviewed articles published in fiscal year 2024, bringing all-time number to nearly 450 KENNEDY SPACE CENTER, Fla.,...
VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased...
SALT LAKE CITY, Jan. 9, 2025 /PRNewswire/ -- Survivor Healthcare, a specialty provider of primary supportive care for cancer patients, has...
SAN FRANCISCO and STRASBOURG, France, Jan. 9, 2025 /PRNewswire/ -- Caresyntax, the world-leading developer of surgical intelligence platforms and Qaelon...
Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer,...
JERSEY CITY, N.J., Jan. 9, 2025 /PRNewswire/ -- Outcomes Matter Innovations, LLC ("OMI") today announced a co-development agreement with Regional...
Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9,...
Stevens brings decades of healthcare leadership and innovation to TechBio company at the forefront of advancing digital precision medicine to...
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025...
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE...
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,...
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health...
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a...
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancerCAMBRIDGE, Mass.,...
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role...